Is CDNA a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for CareDx builds and sells diagnostics (CDNA) rests on Testing-volume growth: Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. Revenue (TTM) is ~$413M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. Whether CDNA is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community. Its core products are AlloSure, a next-generation-sequencing test that measures donor-derived cell-free DNA (dd-cfDNA) to detect kidney and heart transplant injury, and AlloMap, a long-established gene-expression test used by the large majority of U.S. heart-transplant centers. Around these tests the company layers patient-management software, pharmacy services, and a research-and-products franchise, positioning itself as an integrated transplant platform rather than a single-test lab. The investment picture is one of a small-cap growth-plus-turnaround story. Revenue reaccelerated sharply in early 2026 (Q1 up about 39% year over year) and the company posted a rare quarterly profit, while raising full-year guidance and reshaping its portfolio through the Naveris oncology acquisition and the divestiture of its Lab Products unit. The bull case rests on durable testing-volume growth and expanding margins; the bear case centers on reimbursement risk and heavy reliance on the AlloSure and HeartCare franchises. The result is a name with genuine momentum but a valuation that already prices in continued execution.
What's the case for buying CDNA?
1. Testing-volume growth
Testing services are the engine, with volume rising about 17% in Q1 2026 and full-year test volume guided to roughly 224,000 to 229,000. Continued adoption of AlloSure across kidney and heart transplant surveillance is the primary top-line driver.
2. Return to profitability
After years of losses, CareDx delivered positive net income and EPS in Q1 2026 and raised adjusted EBITDA guidance to roughly $43 million to $57 million for the year. If cost discipline holds, the shift from cash burn toward sustained profit is a meaningful re-rating catalyst.
3. Portfolio reshaping
Management is buying Naveris, an HPV-driven solid-tumor diagnostics business (about $34 million in 2025 revenue with 30% to 40% growth potential), while divesting Lab Products for roughly $170 million upfront. This tightens focus on high-value clinical testing and adds an oncology adjacency.
4. Integrated transplant platform
Beyond individual tests, CareDx bundles digital workflow tools, pharmacy services, and patient management, aiming to embed itself deeply in transplant-center operations. This platform breadth is intended to widen its moat against single-test competitors.
What are the risks to CDNA?
Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.
How is CDNA valued? (as of July 2026)
Snapshot for CDNA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$413M
- Q1 2026 revenue: ~$118M (+39% YoY)
- 2026 revenue guidance: ~$447M to $465M
- 2026 adj. EBITDA guidance: ~$43M to $57M
- Net income (TTM): ~-$8M (Q1 2026 positive)
- Market cap: ~$1.1B
CDNA trades at roughly 2.5 to 3 times trailing revenue, a multiple that reflects reaccelerating growth and an early return to profitability rather than deep value. A cash cushion near $200 million and positive adjusted EBITDA guidance give it flexibility, but the trailing net loss means the market is paying for future execution. Reimbursement outcomes are the swing factor for whether the current multiple proves justified.
How do you decide if CDNA is a buy?
Rather than asking whether CDNA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CDNA indirectly through an index or sector ETF before adding more.
For the full picture, see the CDNA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CDNA against your real portfolio and see your actual exposure before deciding.
The bottom line on CDNA
The bottom line: CareDx builds and sells diagnostics's story right now is Testing-volume growth, with revenue (ttm) at ~$413M. If you believe that narrative continues, the call is about sizing CDNA sensibly and checking overlap with what you own; if you doubt it (the risk: reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CDNA with Walnut
Use CareDx builds and sells diagnostics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CDNA a good stock to buy right now?
+
The case for CareDx builds and sells diagnostics right now is Testing-volume growth, with revenue (ttm) at ~$413M. If you believe that thesis holds, CDNA is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does CareDx builds and sells diagnostics do?
+
CareDx builds and sells diagnostics, digital tools, and services for the organ-transplant community.
What are the main risks of CDNA?
+
Reimbursement is the central risk: bears flag potential headwinds of roughly $15 million to $30 million a year from possible coverage or coding changes, which would matter against a revenue base near $413 million. The business is concentrated in the AlloSure and HeartCare franchises, so pricing pressure or a coverage decision there disproportionately affects results. Competition is intensifying, notably from Natera's Prospera test plus Eurofins Transplant Genomics, Devyser, and others, and the rivalry has spilled into litigation. The company remains unprofitable on a trailing-twelve-month basis despite the recent quarterly profit, so the turnaround is early. Integration risk from the Naveris acquisition and execution risk on the Lab Products divestiture add further uncertainty.
What does CareDx (CDNA) actually do?
+
CareDx provides diagnostics and services for the organ-transplant community. Its flagship tests, AlloSure and AlloMap, monitor kidney and heart transplant recipients for signs of rejection, and it also sells patient-management software and pharmacy services to transplant centers.
Is CareDx profitable?
+
It turned a quarterly profit in Q1 2026 with positive net income and EPS, and guided to positive full-year adjusted EBITDA. However, on a trailing-twelve-month basis it was still slightly net-loss-making as of early 2026, so the profitability trend is recent and not yet fully established.
How fast is CareDx growing?
+
Growth reaccelerated sharply in early 2026, with Q1 revenue up about 39% year over year and testing volume up roughly 17%. Full-year 2026 revenue guidance of about $447 million to $465 million implies continued strong double-digit growth.
What is AlloSure and why does it matter?
+
AlloSure is a next-generation-sequencing test that measures donor-derived cell-free DNA in a patient's blood to detect transplant-organ injury without an invasive biopsy. It is the core growth driver of the business and central to CareDx's revenue and competitive position.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CDNA; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.